Four things to know:
1. The acquisition was an all-stock transaction of roughly $109 million in value on the date prior to closing.
2. In the deal, Misonix acquired TheraSkin, Solys Medical’s cellular and tissue-based wound treatment.
3. The acquisition consisted of the issuance of around 5.7 million new shares to former Solys unitholders.
4. Misonix assumed Solsys’ outstanding secured debt of roughly $24 million.
More articles on devices:
Dr. Isaac Karikari: Changing attitudes toward opioids and how physicians can drive change
Dr. Timothy Kremchek to operate on Reds rookie Nick Senzel — 4 insights
Icotec to introduce new pedicle screw system — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
